Population ‐based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non‐metastatic muscle‐invasive bladder cancer
ConclusionA total of 29.6% of MIBC patients are planned for NC with 20.5% not progressing to their surgery. Use of NC has substantially increased over time. IRHs and ATEs remain stubbornly high at 4.2% and 11.5% respectively. Older age and higher CI scores are the strongest predictors of IRHs and ATEs (p < 0.05), not perioperative chemotherapy.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tarik Benidir,
Jaime Herrera ‐Caceres,
Christopher Wallis,
Katherine Lajkosz,
Neil Fleshner Tags: ORIGINAL RESEARCH Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study